Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)
Online ISSN : 1883-7077
Print ISSN : 0910-9153
ISSN-L : 0910-9153
Clinical Efficacy of Prophylactic Administration of a Second-Generation Antihistamine to Patients with Japanese Cedar Pollinosis
a Three-year, Multicenter, Retrospective Study
Shigeharu Fujieda, Takechiyo Yamada, Akihiro Kojima, Mutsuo Kudo, Harumi Suzaki, Yoshiyuki Kadokura, Takeyuki Sanbe, Hidetaka Yoshihashi, Kiyoshi Makiyama, Motofumi Ohki, Toshio Ogoshi, Kimihiro Okubo, Kazuo Yao, Takafumi Yosida, Mamoru Tsukuda, Taku Ohashi, Kayoko Kushita, Aya Hattori, Yoshifumi Ito, Yuki Hamajima, Nobuaki Ohno, Motohiko Suzuki, Yoshihisa Nakamura, Yoshiko Tanaka, Shingo Murakami, Takemitsu Hama, Kenji Dejima, Yasuo Hisa, Sawako Hyo, Katsuhiro Hirakawa, Koji Yajin, Mitsuhiro Okano, Kazunori Nishizaki, Shingo Kataoka, Hideyuki Kawauchi, Koji Matsuura, Tetsuya Tono, Ikuyo Miyanohara, Yuichi Kurono, Hiroshi Takenaka
Author information
JOURNAL FREE ACCESS

2007 Volume 46 Issue 1 Pages 18-28

Details
Download PDF (1445K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Japanese cedar pollinosis (JCP) is a relatively common disease in Japan and is a serious problem between February and April each year. H1 antagonists (antihistamines, including second-generation antihistamines) are used as first-line treatment in most patients. It has recently been recommended that patients who develop severe symptoms of pollinosis every year begin treatment immediately after the start of pollen release or the onset of symptoms. A physician should choose the drug regimen for each patient by selecting from among many second-generation antihistamines according to the amount of pollen release expected during the season and the type and severity of symptoms usually experienced by the patient during the peak season. However, there is wide variation in pollen release among the regions of Japan and from year to year. If constant effectiveness of an antihistamine for patients with JCP were demonstrated by a large-scale multicenter study for several years, it would please both patients with JPC and their physicians.
In this study we investigated the efficacy of the second-generation anti-histamine olopatadine in 1611 patients with JCP attending the clinics of 83 hospitals, for 3 consecutive years. Prophylactic olopatadine was effective against JCP, especially in the season pollen level was low (under 2000/season). In the season when there was a high pollen level, prophylactic olopatadine was effective until the peak pollen release. After one day of therapy olopatadine also significantly improved the nasal symptom scores of patients with moderate to severe symptoms of JCP. These results suggest that olopatadine is a very effective drug for the treatment of JCP.

Content from these authors
© Japan Rhinologic Society
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

The Journal of Japan Rhinologic Society

Share this page
feedback
 Top